47% (53/113) of patients had oestrogen receptor (ER) and/or progesterone receptor (PR) positive, HER2-negative disease; 19% (22/113) had HER2-positive disease; and 34% (38/113) had triple-negative breast cancer (TNBC). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.